1. Inicio
  2. Publicaciones
  3. Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis

Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Fox, ML
  • Garcia-Cadenas, I
  • Perez, AM
  • Villacampa, G
  • Orti, G
  • Roldan, E
  • Vilaseca, AB
  • Martino, R
  • Salamero, O
  • Saavedra, S
  • Hernandez-Boluda, JC
  • Esquirol, A
  • Sierra, J
  • Solano, C
  • Bosch, F
  • Barba, P
  • Valcarcel, D

Grupos

Abstract

In classical reduced-intensity conditioning (RIC) regimens, including the fludarabine and busulphan (BF) combination, sirolimus and tacrolimus (SIR-TAC) as graft vs host disease (GVHD) prophylaxis has shown acceptable results. The outcomes of SIR-TAC in a more intense RIC regimen as Thiotepa-fludarabine-busulfan (TBF) have been hardly investigated. This retrospective study included all consecutive patients receiving an allogeneic hematopoietic stem cell transplantation for myeloid malignancies (January 2009-2017) conditioned with either TBF or BF and receiving SIR-TAC. Patients receiving TBF presented higher non-relapse mortality (31.6 vs 12.3%,p = .01), along with shorter overall survival (51.8% vs 77.8%,p < .01) at 2 years than patients treated with BF. There were no significant differences in the cumulative incidence of grade II-IV acute GVHD or moderate-severe chronic GVHD or relapse between both groups. These results suggest that TBF does not seem to improve the traditional RIC BF regimen, at least when associated with SIR-TAC prophylaxis.

Datos de la publicación

ISSN/ISSNe:
1042-8194, 1029-2403

LEUKEMIA & LYMPHOMA  TAYLOR & FRANCIS LTD

Tipo:
Article
Páginas:
1823-1832
PubMed:
32654570
Factor de Impacto:
0,961 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 2

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Thiotepa-fludarabine-busulfan; sirolimus and tacrolimus; allogeneic hematopoietic cell transplantation; reduce intensity conditioning; graft vs host disease prophylaxis

Campos de Estudio

Cita

Compartir